Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause
Janux Therapeutics' TRACTr platform shows promise with encouraging early data. Check out what leads me to maintain a “Strong ...
pharmaphorum5d
Merck cuts $1bn deal with Janux for cancer T-cell therapies
its TRACTr drugs have been shown to offer the same anti-tumour activity as older T-cell engager drugs, but don’t cause the release of cytokines that can lead to a runaway immune response and ...
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of ...
pharmaphorum9mon
Janux plans $200m offer on back of prostate cancer readout
The first-in-human study is the first readout from the company’s pipeline of tumour-activated TCE (TRACTr) therapies, designed to overcome the limitations of the class in treating solid tumours.
Seeking Alpha1mon
Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation
Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life. Lead candidate JANX007 demonstrates strong ...